氟达拉滨暴露可预测儿童及年轻成人急性白血病CD19 CAR-T细胞治疗后的结局
该回顾性分析纳入26例接受替沙仑赛治疗的复发/难治性B细胞急性淋巴细胞白血病患者,评估淋巴清除期间氟达拉滨累积暴露(AUCT0-∞)与结局的关系。AUCT0-∞<14 mg*h/L为暴露不足,其无白血病生存期、B细胞再生障碍持续时间更短,CD19阳性复发率更高。作者认为优化氟达拉滨暴露可能对CAR-T后无白血病生存有影响,需前瞻性临床试验验证。
要点
- 氟达拉滨累积AUCT0-∞≥14 mg*h/L时事件概率最低,低于该值定义为暴露不足。
- 暴露不足组中位无白血病生存1.8个月,≥14 mg*h/L组为12.9个月(P<.001)。
- 暴露不足组1年内CD19阳性复发率100%,≥14 mg*h/L组为27.4%(P=.0001)。
核心结论
- 氟达拉滨暴露是CAR-T输注后无白血病生存、B细胞再生障碍和CD19阳性复发的预测因素。
- 优化氟达拉滨暴露可能对CAR-T细胞治疗后的无白血病生存有相关影响,需前瞻性临床试验验证。
研究设计与样本
- 回顾性分析,纳入26例接受替沙仑赛治疗的复发/难治性B细胞急性淋巴细胞白血病儿童及年轻成人患者。
- 评估淋巴清除期间氟达拉滨累积暴露(浓度-时间曲线下面积,AUCT0-∞)对临床结局和淋巴细胞动力学的影响。
主要发现
- 氟达拉滨累积AUCT0-∞≥14 mg*h/L时事件概率最低,AUCT0-∞<14 mg*h/L定义为暴露不足。
- 暴露不足组中位无白血病生存1.8个月,AUCT0-∞≥14 mg*h/L组为12.9个月(P<.001)。
- 暴露不足组1年内CD19阳性复发率100%,AUCT0-∞≥14 mg*h/L组为27.4%(P=.0001)。
- 暴露不足组6个月内B细胞再生障碍持续时间更短(77.3% vs 37.3%;P=.009)。
关键数值与推荐
- 累积氟达拉滨AUCT0-∞≥14 mg*h/L为事件概率最低的暴露水平,AUCT0-∞<14 mg*h/L为暴露不足。
- 暴露不足组中位无白血病生存1.8个月 vs AUCT0-∞≥14 mg*h/L组12.9个月(P<.001)。
- 暴露不足组1年内CD19阳性复发率100% vs AUCT0-∞≥14 mg*h/L组27.4%(P=.0001)。
- 暴露不足组6个月内B细胞再生障碍持续时间77.3% vs AUCT0-∞≥14 mg*h/L组37.3%(P=.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出结果需在前瞻性临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The addition of fludarabine to cyclophosphamide as a lymphodepleting regimen prior to CD19 chimeric antigen receptor (CAR) T-cell therapy significantly improved outcomes in patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Fludarabine exposure, previously shown to be highly variable when dosing is based on body surface area (BSA), is a predictor for survival in allogeneic hematopoietic cell transplantation (allo-HCT). Hence, we hypothesized that an optimal exposure of fludarabine might be of clinical importance in CD19 CAR T-cell treatment. We examined the effect of cumulative fludarabine exposure during lymphodepletion, defined as concentration-time curve (AUC), on clinical outcome and lymphocyte kinetics. A retrospective analysis was conducted with data from 26 patients receiving tisagenlecleucel for r/r B-ALL. Exposure of fludarabine was shown to be a predictor for leukemia-free survival (LFS), B-cell aplasia, and CD19-positive relapse following CAR T-cell infusion. Minimal event probability was observed at a cumulative fludarabine AUCT0-∞ ≥14 mg*h/L, and underexposure was defined as an AUCT0-∞ <14 mg*h/L. In the underexposed group, the median LFS was 1.8 months, and the occurrence of CD19-positive relapse within 1 year was 100%, which was higher compared with the group with an AUCT0-∞ ≥14 mg*h/L (12.9 months; P < .001; and 27.4%; P = .0001, respectively). Furthermore, the duration of B-cell aplasia within 6 months was shorter in the underexposed group (77.3% vs 37.3%; P = .009). These results suggest that optimizing fludarabine exposure may have a relevant impact on LFS following CAR T-cell therapy, which needs to be validated in a prospective clinical trial.
引用
- Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022. PMID: 35134115. doi:10.1182/bloodadvances.2021006700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。